Stome:
I know what you are saying. Time is the enemy of any BP right now as it pertains to PPHM. In most cases a BP wants a biotech to bring the drug as far along as possible before partnership to mitigate risk. However in the case of bavi being a potential drug for all solid tumor cancers and many other indications, the more developed it becomes the more expensive it becomes to acquire.
Plus when the very smart people do realize what we have here, I have to agree that shares will be in short supply and up we go. I cant see a reason we would even conside anything less than $20B, even then that is a low ball number in my opinion. But if that is the sell out price, I can retire now in my 40's.
Market Data 
Markets 
AI
